Systematic review of economic evaluation studies of drug-based non-malignant chronic pain treatment.

CONCLUSION: There are limitations to the success of making appropriate recommendations about which treatment is most cost-effective due to great variability between treatments, pain syndromes, and drug dosages. To ensure correct resource allocation as well the best benefit for patients, uniform and standardized approaches of cost and outcome measurement in economic evaluations of chronic are needed. PMID: 31322067 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31322067?dopt=Abstract

Source: Current Pharmaceutical Biotechnology - July 15, 2019 Category: Biotechnology Authors: Backhaus I, Mannocci A, La Torre G Tags: Curr Pharm Biotechnol Source Type: research